Table 4.

Summary of VSLI versus VCR antitumor activity in 18 human tumor xenograft models

Tissue origin	Tumor modela	Scheduleb	Sensitivity to VCR	Dose-dependent antitumor activity	Relative antitumor activity
Leukemia	P388c (IP)	Single	Moderate	VSLI	VSLI > VCR*
Lymphoma	Namalwa	q7d × 2, q7d × 3	Moderate	VSLI, VCR	VSLI > VCR*
Lymphoma	RL	q7d × 3	High	VSLI, VCR	VSLI > VCR
Lymphoma	DoHH2	q7d × 3	High	VSLI, VCR	VSLI = VCR
Lymphoma	SR	q7d × 2	High	None	Unable to assess
SCLC	LX-1	Single	Weak	VSLI	VSLI > VCR
SCLC	LX-1	q7d × 3	Moderate	NA	VSLI > VCR*
SCLC	NCI-H69	Single	High	VSLI, VCR	VSLI = VCR
SCLC	DMS273	Single	Moderate	VSLI, VCR	VSLI = VCR
Breast carcinoma	MX-1	Single	Moderate	VSLI, VCR	VSLI > VCR
Breast carcinoma	MX-1	q21d × 2, q21d × 3	High	VSLI, VCR	VSLI > VCR*
Breast carcinoma	MX-1	q7d × 3	High	VSLI, VCR	VSLI > VCR
Breast carcinoma	MX-1	q7d × 3	High	VSLI, VCR	VSLI > VCR
Renal carcinoma	RXF393	Single	Weak	VSLI	VSLI > VCR*
Prostate carcinoma	PC-3	Single	Moderate	VSLI	VSLI > VCR
Prostate carcinoma	PC-3	q7d × 3	High	VSLI, VCR	VSLI = VCR
Prostate carcinoma	PC-3 (OT)	q7d × 3	Moderate	None	VSLI ≥ VCR
Kaposi’s sarcoma	My1	q7d × 3	Weak	VSLI, VCR	VSLI ≥ VCR
Melanoma	B16/BL6c (IV)	Single	Not sensitive	None	Unable to assess
Melanoma	B16/BL6c	q7d × 3	Not sensitive	None	Unable to assess
NSCLC	NCI-H460	Single	Not sensitive	None	Unable to assess
Colon carcinoma	HT29	Single	Not sensitive	None	Unable to assess
Multiple myeloma	LAGκ-1A	q7d × 3	Moderate	VSLI	VSLI > VCR
Multiple myeloma	LAGκ-1B	q7d × 3	Not sensitive	VSLI	VSLI > VCR

IV intravenous, IP intraperitoneal, NA not applicable (only one dose tested), OT orthotopic, SCLC small-cell lung cancer

^aTumors were human xenograft models implanted subcutaneously, unless specified

^bRepeat-dose schedules were once a week for 2 or 3 cycles (q7d × 2 or q7d × 3) or every 3 weeks for 2 or 3 cycles (q21d × 2 or q21d × 3). ^cMurine tumor model

* Statistically significant difference (p < 0.05)